Caplin Point Laboratories Ltd Q1 FY27 Share Price & Earnings Call Analysis

Management guidance · Q1 FY27 call

Caplin Point Laboratories Ltd ranks #9 of 32 in Pharmaceuticals & Biotechnology on what management guided

Revenue growth 20–40%Margin flat

Leading Pharmaceuticals & Biotechnology companies on guidance

  1. 1.Accretion Pharmaceuticals LtdRevenue growth 40%+
  2. 2.Revenue growth 40%+
  3. 3.Revenue growth 40%+
Full Pharmaceuticals & Biotechnology ranking →Check your portfolio against these rankings →All companies ranked →

Sign up free to see every company in the sector ranking and track Caplin Point Laboratories Ltd.

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

62out of 100

Momentum score · price trend

62 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,904 stocks
Last 12 months+14.2%67%
Last 6 months+30.0%75%
Last 3 months−12.0%26%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,904 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Caplin Point Laboratories Ltd: 0.4 × 67 + 0.4 × 75 + 0.2 × 26 = 62.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 16 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Financials of Caplin Point Laboratories Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Caplin Point Laboratories Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +389395410436453459483493502510534543600
Expenses +265269273293308307318331334332345353396
Operating Profit124127137142145152165162168178189190204
OPM %32%32%34%33%32%33%34%33%33%35%35%35%34%
Other Income +11122117171921312623303428
Interest0000000000000
Depreciation11111214161617161716181919
Profit before tax124127146145146154168177177184201204213
Tax %18%18%20%18%17%19%22%21%18%18%20%19%19%
Net Profit +101104116120121125131140145151160166173
EPS in Rs13.4513.6215.1315.4316.0116.3117.2118.2818.7620.1020.3221.5622.38

Financials of Caplin Point Laboratories Ltd

Profit & Loss

Annual income statement trend

Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +2522394025406498631,0611,2691,4671,6941,9372,187
Expenses +1921752763454176037328741,0251,1421,2871,426
Operating Profit6064125195232260329395442552651761
OPM %24%27%31%36%36%30%31%31%30%33%34%35%
Other Income +34101319412338556692116
Interest101110211111
Depreciation8713192332374745536673
Profit before tax5360121188227269314386451564677803
Tax %23%24%21%23%22%20%20%20%16%18%20%19%
Net Profit +414696145177215251308377461541650
EPS in Rs5.436.0512.6519.1523.3528.4232.0339.5649.5760.1970.5684.36
Dividend Payout %18%20%12%10%9%9%9%10%9%8%8%5%

Financials of Caplin Point Laboratories Ltd

Balance Sheet

Capital structure and asset base

Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital151515151515151515151515
Reserves781132103495828589541,2521,6492,0842,6193,571
Borrowings +2211361132352192222192225
Other Liabilities +134137133136109139159250305380352454
Total Liabilities2292673585007431,1261,3641,7362,1912,6983,2084,045
Fixed Assets +113144152169227272305287280453546605
CWIP31031510201418221117144209
Investments00174770611189281376590859
Other Assets +851221862694367721,0331,3431,4101,7531,9282,373
Total Assets2292673585007431,1261,3641,7362,1912,6983,2084,045

Financials of Caplin Point Laboratories Ltd

Cash Flows

Operating, investing and financing cash movement

Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +504268668345269337271318432523
Cash from Investing Activity +-23-6-36-69-100-54-30-377-216-319-333-582
Cash from Financing Activity +-9-14-7-129080-24-41-28-38-38-46
Net Cash Flow192325-147370215-8127-3961-106
Free Cash Flow2434431818-3219524678173241275
CFO/OP103%92%73%53%54%38%102%106%81%77%86%88%

Financials of Caplin Point Laboratories Ltd

Ratios

Working capital efficiency and return ratios

Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days81230859097969198117119138
Inventory Days3757444447210139149159183159181
Days Payable11216815514476576810284116103125
Cash Conversion Cycle-67-99-81-1661251166138173184175194
Working Capital Days-128-114-2947104167145165144166174263
ROCE %68%62%68%63%45%33%28%28%26%26%26%25%

Continue your research

What Caplin Point Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Granules India Ltd (Q2 FY27)

    Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…

  • Wanbury Ltd (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn Ltd (Q2 FY26)

    42.35 crore, up 21.98% year-on-year from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q2 FY26 investor presentation — and how it ran

  • Senores Pharmaceuticals Ltd (Q2 FY26)

    Earnings (PAT) growth has been very strong recently (e.g., 131% Y-o-Y growth in Q2) with sustained profitability momentum. Key concall takeaways from Senores…

Compare:vs Torrent Pharmaceuticals Ltdvs Laurus Labs Ltdvs Cipla Ltd